AccessibilityHelpAbout Us

Tessera Defense And Homeland Security(NYSEMKT) HLSQ

Market Cap$2.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-99%
1 Month-34%
$0.85
-12.39%
-0.12Today
Tessera Defense And Homeland Security last closing stock price
MetricPriceDate
Last closeUSD 0.972026-09-15
Tessera Defense And Homeland Security stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-37.61%USD 1.552026-09-08
1 month-34.21%USD 1.472026-08-14
3 month-82.42%USD 5.502026-06-17
Year to date-94.83%USD 18.702025-12-31
1 year-98.95%USD 92.512025-09-15
3 year-99.86%USD 703.002023-09-15
5 year-99.98%USD 6,061.002021-09-16
Since inception-99.99%USD 18,335.002019-03-13

Tessera Defense And Homeland Security Financials at a Glance

Market Cap

$2.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.33

Net Income (TTM)

-$45.49

EPS (TTM)

-$216.64

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$0.85

Volume

333,584.849

Open

$0.97

Previous Close

$0.97

Daily Range

$0.83 - $0.98

52-Week Range

$0.83 - $122.93

Estimated Earnings Date

Aug 19, 2026

HLSQ News

Foolcom-Featured.png

BiomX Posts Q2 Loss With 14% Cost Drop

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tessera Defense And Homeland Security

BiomX develops treatments that use viruses called phages to target harmful bacteria. Its therapies aim to help people with chronic diseases like cystic fibrosis and certain skin conditions. These products are designed for patients who do not respond to standard antibiotics.

Bug Busters: Products and Services

  • BX004 (Inhaled phage therapy): Treats lung infections in cystic fibrosis patients; no revenue contribution as of Q2 2025.
  • BX211 (Phage for diabetic foot infections): Targets Staphylococcus aureus in diabetic wounds; no revenue contribution as of Q2 2025.
  • BX003 (Oral phage cocktail): Aims at gut bacteria linked to inflammatory bowel disease and liver disease; no revenue contribution as of Q2 2025.
  • Colorectal Cancer Program: Uses engineered phages to target bacteria in tumors; preclinical stage, no revenue as of Q2 2025.
  • Personalized phage therapy: Custom treatments for joint infections; program currently on hold, no revenue as of Q2 2025.

Growing Pains and Gains: Expansion Moves

  • Acquired Adaptive Phage Therapeutics in March 2024, expanding U.S. pipeline and assets.
  • Launched Phase 2b trial for BX004 in cystic fibrosis in July 2025.
  • Completed Phase 2 trial for BX211 in diabetic foot infections in 2025.
  • Discontinued BX005 (atopic dermatitis) in 2024 to focus on core programs.
  • Expanded clinical collaborations, including support for a U.S. National Institutes of Health study in cystic fibrosis.

Why BiomX Is a Bit Different

BiomX uses a proprietary platform to quickly develop phage therapies for hard-to-treat bacterial infections. The company combines broad-use and personalized approaches, aiming to address both common and rare patient needs. Its regulatory designations and U.S. expansion support its position in the clinical-stage phage therapy field.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025 and Q2 2024, but was negative $90,000 in Q2 2023.
  • Operating loss was $7 million in Q2 2025, improving 23.6% from Q2 2024.
  • Cash and equivalents were $14 million as of June 30, 2025, down 94.1% from Q2 2024.
  • Net cash used in operations was $14.8 million for H1 2025, compared to $22.6 million for H1 2024.

Bottom Line

BiomX remains a pre-commercial company focused on developing phage-based therapies for chronic bacterial diseases. Its recent acquisitions and clinical progress show adaptability, but ongoing losses and funding needs remain key challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Michael Oster

Website

www.biomx.com

Headquarters

Dover, DE 19958, US

HLSQ Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-299.52%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.73M

Volume

333.58K

Avg. Volume

412.94K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Tessera Defense And Homeland Security Performance Analysis

Tessera Defense And Homeland Security annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tessera Defense And Homeland Security annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,802.19-31.9%
20232023-12-31USD -968.66-46.3%
20242024-12-31USD -280.23-71.1%
20252025-12-31USD -221.94-20.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.33

N/A

Gross Profit

$0.10

-0.3%

Gross Margin

29.22%

N/A

Market Cap

$2.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.22

N/A

Employees

20

N/A

Net Income

-$3.85

+0.6%

EBITDA

-$5.41

+0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.72

-84.8%

Total Debt

$3.37

+0.4%

Accounts Receivable

$0.33

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.26

+0.0%

Short Term Debt

$3.11

+2.5%

Return on Assets

-136.51%

+3.1%

Return on Invested Capital

473.69%

-5.1%

Free Cash Flow

-$1.17

+0.2%

Operating Cash Flow

-$1.17

+0.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,587.01-0.00%
^DJIDJI
$52,024.29-0.01%
^IXICNASDAQ
$25,994.03-0.01%
BTCBitcoin
$76,604.00-0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
MEDSDataMEDS Ai
$9.40+480.25%
RETOReTo Eco-Solutions
$16.66+495.00%
INTCIntel
$101.59+4.58%
NOKNokia
$10.15+3.15%

Questions About HLSQ

What is the current price of Tessera Defense And Homeland Security?

Tessera Defense And Homeland Security is trading at $0.86 per share.

What is the 52-week range for Tessera Defense And Homeland Security?

Over the past 52 weeks, Tessera Defense And Homeland Security has traded between $0.83 and $122.93.

How much debt does Tessera Defense And Homeland Security have?

As of the most recent reporting period, Tessera Defense And Homeland Security reported total debt of $3.37M.

How much cash does Tessera Defense And Homeland Security have on hand?

Tessera Defense And Homeland Security reported $347.00K in cash and cash equivalents in its most recent financial results.

What is Tessera Defense And Homeland Security’s dividend yield?

Tessera Defense And Homeland Security does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services